全文获取类型
收费全文 | 980篇 |
免费 | 81篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 62篇 |
妇产科学 | 21篇 |
基础医学 | 89篇 |
口腔科学 | 49篇 |
临床医学 | 73篇 |
内科学 | 212篇 |
皮肤病学 | 18篇 |
神经病学 | 41篇 |
特种医学 | 107篇 |
外科学 | 192篇 |
综合类 | 29篇 |
预防医学 | 54篇 |
眼科学 | 14篇 |
药学 | 60篇 |
中国医学 | 1篇 |
肿瘤学 | 42篇 |
出版年
2023年 | 7篇 |
2022年 | 6篇 |
2021年 | 23篇 |
2020年 | 17篇 |
2019年 | 22篇 |
2018年 | 17篇 |
2017年 | 13篇 |
2016年 | 22篇 |
2015年 | 22篇 |
2014年 | 23篇 |
2013年 | 32篇 |
2012年 | 45篇 |
2011年 | 46篇 |
2010年 | 34篇 |
2009年 | 47篇 |
2008年 | 31篇 |
2007年 | 52篇 |
2006年 | 29篇 |
2005年 | 33篇 |
2004年 | 22篇 |
2003年 | 24篇 |
2002年 | 25篇 |
2001年 | 21篇 |
2000年 | 32篇 |
1999年 | 20篇 |
1998年 | 26篇 |
1997年 | 41篇 |
1996年 | 39篇 |
1995年 | 20篇 |
1994年 | 23篇 |
1993年 | 21篇 |
1992年 | 12篇 |
1991年 | 16篇 |
1990年 | 11篇 |
1989年 | 24篇 |
1988年 | 24篇 |
1987年 | 15篇 |
1986年 | 19篇 |
1985年 | 13篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 9篇 |
1978年 | 7篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1970年 | 3篇 |
1908年 | 8篇 |
1907年 | 3篇 |
排序方式: 共有1078条查询结果,搜索用时 187 毫秒
1.
Peter D. Le Roux David S. Jardine Paul M. Kanev John D. Loeser 《Child's nervous system》1991,7(1):34-39
We reviewed the results of all pediatric patients undergoing intracranial pressure (ICP) monitoring in a 2-year period at our institution. The outcome of patients suffering hypoxia or ischemic injuries (HII) is compared to those suffering non-hypoxic or non-ischemic injuries (NHII). Thirty-four patients had ICP monitors placed during the study period. Inconplete patient information led to the exclusion of 5 patients. An additional 5 patients were excluded because no measures to control ICP were taken after the monitor was placed. Twenty-four patients required treatment for raised ICP (hyperventilation, 24; mannitol, 19; barbiturate coma, 6). Admission Glasgow Coma Score in patients suffering HII (median score 5) and NHII (median score 6) were not significantly different (Mann-Whitney U Test). Only 2 of 8 patients with HII were near-drowning vietims. The remaining 6 had HII from other causes (5 survivors of various forms of asphyxia and 1 of cardiac arrest). All 8 patients had poor outcomes (1 severely disabled; 7 died). The 16 patients with NHII had a variety of diagnoses (6 trauma, 5 encephalitis, 4 bacterial meningitis, 1 diabetic ketoacidosis). Among these, 6 had good outcomes and 10 poor outcomes (2 severely disabled, 2 vegetative, and 6 died). The difference in outcome between patients with NHII and HII is significant at P=0.059 (Fischer Exact test). Patients with NHII may benefit from ICP monitoring. Patients with HII from near-drowning and other causes did not appear to benefit from ICP monitoring and interventions directed at controlling ICP. 相似文献
2.
3.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients 总被引:1,自引:0,他引:1
A. Åsberg A. Humar H. Rollag A. G. Jardine H. Mouas M. D. Pescovitz D. Sgarabotto M. Tuncer I. L. Noronha A. Hartmann 《American journal of transplantation》2007,7(9):2106-2113
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study. 相似文献
4.
The role of growth factors and cytokines in the impaired healing of chronic leg ulcers remains uncertain. The aim of this study was to determine whether changes in the amount and location of cytokines and growth factors may be associated with impaired healing in chronic leg ulcers. Biopsies from leg ulcers of 21 patients and from normal skin of nine healthy volunteers were examined immunohistochemically for selected growth factors and cytokines. Greater staining intensity was found in keratinocytes at the edges of ulcers compared to normal skin, or skin adjacent to the ulcers. Staining at the ulcer edge was more intense in nonhealing ulcers for only vascular endothelial growth factor and platelet-derived growth factor, whereas staining in the adjacent skin was more intense for all factors in the nonhealing phase. For all factors staining was cytoplasmic, suggesting production in these areas. This study shows up-regulation of the production of cytokines and growth factors in keratinocytes of chronic leg ulcers that is greater when the ulcers are nonhealing. 相似文献
5.
6.
7.
8.
9.
10.
Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 总被引:1,自引:0,他引:1
Collins CE Benson MJ Burnham WR Rampton DS 《Alimentary pharmacology & therapeutics》1996,10(3):315-320
BACKGROUND: Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option. METHODS: Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease. RESULTS: Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147- 325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61- 140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64- 206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM). CONCLUSION: Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease. 相似文献